Factor (test/reference) | All Antipsychotics | Olanzapine group | Non-olanzapine group | ||||||||
| OR | 95% CI | p-value | OR | 95% CI | p-value | OR | 95% CI | p-value | ||
Gender (female/male) | 1.204 | 0.920 - 1.576 | 0.175 | 1.163 | 0.803 - 1.686 | 0.424 | 1.370 | 0.913 - 2.056 | 0.129 | ||
Age (units = 10 years old) | 0.871 | 0.797 - 0.953 | 0.003 | 0.843 | 0.743 - 0.957 | 0.008 | 0.916 | 0.804 - 1.044 | 0.187 | ||
Onset of illness (recurrent/initial) | 1.145 | 0.854 - 1.535 | 0.366 | 0.994 | 0.664 - 1.488 | 0.976 | 1.294 | 0.836 - 2.004 | 0.247 | ||
Outpatient or inpatient status (outpatients/inpatients) | 0.508 | 0.383 - 0.675 | <0.001 | 0.622 | 0.416 - 0.929 | 0.020 | 0.398 | 0.264 - 0.601 | <0.001 | ||
Prior use of any antipsychotics* (yes/no) | 0.693 | 0.516 - 0.930 | 0.015 | 0.549 | 0.366 - 0.824 | 0.004 | 0.886 | 0.568 - 1.383 | 0.595 | ||
CGI-S Schizophrenia Score** (units = 1) | 1.049 | 0.900 - 1.223 | 0.540 | 1.078 | 0.879 - 1.322 | 0.468 | 1.058 | 0.830 - 1.348 | 0.650 | ||
Use of anti-parkinson agents** (yes/no) | 0.844 | 0.553 - 1.288 | 0.431 | 0.500 | 0.250 - 0.999 | 0.050 | 1.155 | 0.644 - 2.071 | 0.629 | ||
Use of antidepressants** (yes/no) | 0.827 | 0.472 - 1.448 | 0.506 | 1.243 | 0.553 - 2.792 | 0.599 | 0.576 | 0.252 - 1.315 | 0.190 | ||
Use of anti-anxiety/sleep agents** (yes/no) | 0.860 | 0.653 - 1.133 | 0.285 | 0.988 | 0.679 - 1.437 | 0.950 | 0.707 | 0.463 - 1.079 | 0.108 | ||
Use of antiepileptic agents** (yes/no) | 1.088 | 0.733 - 1.614 | 0.677 | 1.719 | 0.971 - 3.044 | 0.063 | 0.821 | 0.457 - 1.475 | 0.509 | ||
Use of mood-stabilizing drugs** (yes/no) | 0.987 | 0.420 - 2.322 | 0.977 | 0.335 | 0.076 - 1.481 | 0.149 | 1.837 | 0.551 - 6.128 | 0.323 | ||
Treatment (Non-olanzapine/Olanzapine) | 1.416 | 1.086 - 1.846 | 0.010 |
|
|
|
|
|
| ||